16537results about "Group 5/15 element organic compounds" patented technology

An organometallic complex and an organic light-emitting element containing the complex which has a very high efficiency, a high luminance, and durability. The organic light-emitting element has an anode, a cathode, and a layer including an organic compound sandwiched between the anode and cathode. The layer containing the organic compound includes at least one organometallic complex represented by General Formula [I] below.

An organic electroluminescent device having a pair of electrodes and at least one organic layer interposed between the pair of electrodes, in which the at least one organic layer contains at least one compound represented by formula (I):

• • wherein, Z¹ and Z² each independently represent a nitrogen-containing aromatic six-membered ring coordinated to the platinum through a nitrogen atom; Q¹ represents a group of atoms necessary for forming, together with the —C—C—, a nitrogen-containing aromatic five-membered ring; L¹ represents a single bond or a divalent linking group; and n is 0 or 1.

Provided are modulators of TLRs of Formula II:

pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

As a novel substance having a novel skeleton, an organometallic complex with high emission efficiency which achieves improved color purity by a reduction of half width of an emission spectrum is provided. One embodiment of the present invention is an organometallic complex in which a β-diketone and a six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom are ligands. In General Formula (G1), X represents a substituted or unsubstituted six-membered heteroaromatic ring including two or more nitrogen atoms inclusive of a nitrogen atom that is a coordinating atom. Further, R¹ to R⁴ each represent a substituted or unsubstituted alkyl group having 1 to 6 carbon atoms.

Metal films are deposited with uniform thickness and excellent step coverage. Copper metal films were deposited on heated substrates by the reaction of alternating doses of copper(I) NN′-diisopropylacetamidinate vapor and hydrogen gas. Cobalt metal films were deposited on heated substrates by the reaction of alternating doses of cobalt(II) bis(N,N′-diisopropylacetamidinate) vapor and hydrogen gas. Nitrides and oxides of these metals can be formed by replacing the hydrogen with ammonia or water vapor, respectively. The films have very uniform thickness and excellent step coverage in narrow holes. Suitable applications include electrical interconnects in microelectronics and magnetoresistant layers in magnetic information storage devices.

An organometallic complex is provided by which favorable red-color light emission can be obtained. Further, an organometallic complex having a peak of light emission at about 620 nm is provided because the wavelength of light which is perceived as excellent red-color light is about 620 nm. Furthermore, an organometallic complex is provided by which red-color light emission with high luminous efficiency (cd/A) can be obtained. An organometallic complex represented by the following general formula (G2) and a light-emitting element, a light-emitting device, and an electronic device including the organometallic complex represented by the following general formula (G2) are provided.

The present invention relates to organic light emitting devices (OLEDs), and more specifically to phosphorescent organic materials used in such devices. More specifically, the present invention relates to emissive phosphorescent material which comprise at least one tridentate ligand bound to a metal center, wherein at least one of the bonds to the tridentate ligand is a carbon-metal bond.

Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate and boranophosphate linkages are disclosed.

A coated nanocrystal capable of light emission includes a substantially monodisperse nanoparticle selected from the group consisting of CdX, where x=S, Se, Te and an overcoating of ZnY, where Y=S, Se, uniformly deposited thereon, said coated nanoparticle characterized in that when irradiated the particles exhibit photoluminescence in a narrow spectral range of no greater than about 60 nm, and most preferably 40 nm, at full width half max (FWHM). The particle size of the nanocrystallite core is in the range of about 20 Å to about 125 Å, with a deviation of less than 10% in the core. The coated nanocrystal exhibits photoluminescence having quantum yields of greater than 30%.

Processes are provided for producing bismuth-containing oxide thin films by atomic layer deposition. In preferred embodiments an organic bismuth compound having at least one monodentate alkoxide ligand is used as a bismuth source material. Bismuth-containing oxide thin films can be used, for example, as ferroelectric or dielectric materials in integrated circuits and as superconductor materials.

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Fast and highly accurate mass spectrometry-based processes for detecting a particular nucleic acid sequence in a biological sample are provided. Depending on the sequence to be detected, the processes can be used, for example, to diagnose a genetic disease or chromosomal abnormality; a predisposition to a disease or condition, infection by a pathogenic organism, or for determining identity or heredity.

Described herein are precursors and methods for forming silicon-containing films. In one aspect, the precursor comprises a compound represented by one of following Formulae A through E below:

In one particular embodiment, the organoaminosilane precursors are effective for a low temperature (e.g., 350° C. or less), atomic layer deposition (ALD) or plasma enhanced atomic layer deposition (PEALD) of a silicon-containing film. In addition, described herein is a composition comprising an organoaminosilane described herein wherein the organoaminosilane is substantially free of at least one selected from the amines, halides (e.g., Cl, F, I, Br), higher molecular weight species, and trace metals.

Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.

An isoreticular metal-organic framework (IRMOF) and method for systematically forming the same. The method comprises the steps of dissolving at least one source of metal cations and at least one organic linking compound in a solvent to form a solution; and crystallizing the solution under predetermined conditions to form a predetermined IRMOF. At least one of functionality, dimension, pore size and free volume of the IRMOF is substantially determined by the organic linking compound.

An organic EL device includes a luminescence layer containing, as a luminescent material allowing a high-luminescence and high-efficiency luminescence for a long period of time, a metal coordination compound represented by the following formula (1): LmML'n, wherein M denotes Ir, Pt, Ph or Pd; L denotes a bidentate ligand; L' denotes a bidentate ligand different from L; m is an integer of 1, 2 or 3; and n is an integer of 0, 1 or 2 with the proviso that the sum of m and n is 2 or 3. The partial structure MLm is represented by a formula (2) or a formula (3) shown below, and the partial structure ML'n is represented by a formula (4) or a formula (5) shown below: wherein CyN1, CyN2 and CyN3 independently denote a substituted or unsubstituted cyclic group containing a nitrogen atom connected to M; CyN4 denotes a cyclic group containing 8-quinoline or its derivative having a nitrogen atom connected to M; CyC1, CyC2 and CyC3 independently denote a substituted or unsubstituted cyclic group containing a carbon atom connected to M, with the proviso that the metal coordination compound is represented by the formula (2) when n is 0.

A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:

wherein

• [0001]
  • Base is a purine or pyrimidine base;
  [0002]
  • R¹ is OH, H, OR³, N₃, CN, halogen, including F, or CF₃, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;
  [0003]
  • R² is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R² is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and
  [0004]
  • R³ is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

Provided is a novel substance that can emit phosphorescence. Alternatively, provided is a novel substance with high emission efficiency. An organometallic complex in which a 4-arylpyrimidine derivative is a ligand and iridium is a central metal is provided. Specifically, an organometallic complex having a structure represented by a general formula (G1) is provided. In the general formula (G1), R¹ represents a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms or a substituted or unsubstituted aryl group having 6 to 10 carbon atoms, R² represents any of hydrogen, a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and a substituted or unsubstituted phenyl group, R³ represents hydrogen or a substituted or unsubstituted alkyl group having 1 to 4 carbon atoms, and Ar¹ represents a substituted or unsubstituted arylene group having 6 to 10 carbon atoms.

Disclosed are a blue phosphorescent compound with a high color purity and a high efficiency, and an organic electroluminescent device using the same. The blue phosphorescent compound is represented by the following Formula:

wherein R1 to R5 are each independently hydrogen (H), fluorine (F), chlorine (Cl), bromine (Br), a cyano group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C6 to C20 substituted or unsubstituted aromatic group, a C5 to C20 substituted or unsubstituted heterocyclic group, a C1 to C6 amine group, a C6 to C20 aromatic-substituted amine group, or a C5 to C20 heterocycle-substituted amine group, X is selected from nitrogen (N), oxygen (O), phosphorous (P) and sulfur (S) atoms, at least one of A1, A2, A3 and A4 is nitrogen (N), and the remaining are selected from hydrogen (H)-substituted carbon, and alkyl or alkoxy-substituted carbon, L is a monodentate or bidentate ligand and n is 1 to 3.

A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.

A composition comprising dihydropyrazinyl anions that can be coordinated as 6 electron ligands to a broad range of different metals to yield volatile metal complexes for ALD and CVD depositions are described herein. Also described herein are undeprotonated dihydropyrazines that can coordinate to metals as stabilizing neutral ligands. In one embodiment, the composition is used for the direct liquid injection delivery of the metal dihydropyrazinyl complex precursor to the chamber of an ALD or CVD chamber for the deposition of metal-containing thin films such as, for example, ruthenium or cobalt metal films.